(Press-News.org) Health policies which favour using ranibizumab for treating eye disease in older people over safety concerns for a cheaper alternative should take account of a new Cochrane Review published today. The researchers looked at the results of studies which compared the safety of two drugs used for treating age-related macular degeneration, ranibizumab and bevacizumab. Contrary to what was argued by some experts the review has found that the cheaper drug, bevacizumab, does not appear to increase deaths or serious side-effects compared with ranibizumab in people with neovascular age-related macular degeneration.
Neovascular macular degeneration is a progressive and chronic disease of the eye, and a leading cause of blindness in older people. About one in 10 people with macular degeneration suffers legal blindness. Bevacizumab is a drug that has been developed to treat cancer, while ranibizumab is marketed specifically for age-related macular degeneration. The two drugs are better known by their brand names Avastin® (bevacizumab) and Lucentis® (ranibizumab). The authors conclude that health policies that favour the much more costly ranibizumab instead of bevacizumab for macular degeneration, for reasons of safety, are not supported by current randomised controlled trial evidence. A larger Cochrane Review, which will assess additional sources of evidence, is now planned to help reduce the remaining uncertainties around the relative benefits and safety of these drugs.
Bevacizumab and ranibizumab are related biological drugs that work to prevent the abnormal growth and swelling of blood vessels that are characteristic signs of macular degeneration. Although the beneficial effects of the two drugs are believed to be similar, only ranibizumab has been licensed as a treatment for macular degeneration; bevacizumab is currently approved only as a cancer therapy. Despite this, an unlicensed preparation of bevacizumab is often used off-label as treatment for macular degeneration, because it is cheaper than ranibizumab. It has been suggested that the two drugs have different safety profiles, such that bevacizumab might cause more systemic harms, and the review investigated this concern.
Lorenzo Moja, from the University of Milan, stated "This review represents an important step forward in the knowledge about differences in systemic harms between bevacizumab and ranibizumab and mitigate past disputes around evidence. The review authors were able to collect evidence from nine trials, including three unpublished studies, while most other reviews focus primarily on published data". He continues "This result was possible through the collaborative effort of researchers across several countries (France, Germany, Italy, UK, and USA), many of who were involved in the original trials. It shows a remarkable level of commitment of trialists and healthcare systems to answer an important clinical question. I am unaware of other examples with such a large number of head-to-head non-industry sponsored RCTs".
Editor in Chief of The Cochrane Library, Dr David Tovey, added "This review addresses a question of immense importance to health systems in many countries. One of the many considerations in decision-making at policy level is not just understanding how effective treatments are, but also weighing up evidence of their safety."
The review included nine randomised controlled trials (RCTs), none of which were supported by manufacturers of either treatment, involving a total of 3665 participants, comparing bevacizumab with ranibizumab. The drugs were given for up to two years. The review found the systemic safety of bevacizumab for macular degeneration appeared to be similar to that of ranibizumab, except for gastrointestinal disorders. Although no statistically significant differences between the treatments were found, the review does not exclude the possibility that either treatment is less harmful than the other. The researchers estimated that if 1000 people were treated with ranibizumab for one to two years, 34 would die; if treated instead with bevacizumab, between 27 and 53 would die. If 1000 people were treated with ranibizumab, 222 would experience one or more serious systemic adverse events. If 1000 people were treated instead with bevacizumab, between 200 and 291 would experience such an event.
They rated the overall quality of the evidence as low to moderate because of the uncertainty of the findings, and due to other study limitations. Additionally, the review authors indicated that they could not fully assess the quality of three of the studies as they had not yet been published.
INFORMATION: END
Cheaper alternative to licensed drug for treating eye disease has similar side-effects
2014-09-15
ELSE PRESS RELEASES FROM THIS DATE:
Study sheds new light on why batteries go bad
2014-09-15
Menlo Park, Calif. — A comprehensive look at how tiny particles in a lithium ion battery electrode behave shows that rapid-charging the battery and using it to do high-power, rapidly draining work may not be as damaging as researchers had thought – and that the benefits of slow draining and charging may have been overestimated.
The results challenge the prevailing view that "supercharging" batteries is always harder on battery electrodes than charging at slower rates, according to researchers from Stanford University and the Stanford Institute for Materials & Energy Sciences ...
Marijuana users who feel low get high
2014-09-15
PISCATAWAY, NJ – Adolescents and young adults who smoke marijuana frequently may attempt to manage negative moods by using the drug, according to a study in September's Journal of Studies on Alcohol and Drugs.
"Young people who use marijuana frequently experience an increase in negative affect in the 24 hours leading up to a use event, which lends strong support to an affect-regulation model in this population," says the study's lead author Lydia A. Shrier, M.D., M.P.H., of the division of adolescent and young adult medicine at Boston Children's Hospital.
She notes ...
Hypersensitivity to non-painful events may be part of pathology in fibromyalgia
2014-09-15
New research shows that patients with fibromyalgia have hypersensitivity to non-painful events based on images of the patients' brains, which show reduced activation in primary sensory regions and increased activation in sensory integration areas. Findings published in Arthritis & Rheumatology, a journal of the American College of Rheumatology (ACR), suggest that brain abnormalities in response to non-painful sensory stimulation may cause the increased unpleasantness that patients experience in response to daily visual, auditory and tactile stimulation.
Fibromyalgia ...
New knowledge of genes driving bladder cancer points to targeted treatments
2014-09-15
The story of cancer care seems so simple: find the mutated gene that causes cancer and turn it off or fix it. But rarely does a single gene cause cancer. More often, many genes are altered together to drive the disease. So the challenge becomes sorting out which altered genes are the most to blame in which cancers. A collaborative study between researchers at the University of Colorado Cancer Center and the National Cancer Institute (NCI) published today in the journal Clinical Cancer Research takes an important step toward answering this question in bladder cancer.
Specifically, ...
Identifying a better message strategy for dissuading smokers: Add the positive
2014-09-15
WASHINGTON — Which is more likely to convince a smoker to quit? The words, "Warning: cigarettes cause cancer" beneath the image of an open mouth with a cancerous lesion and rotten teeth, or the same image with the words, "Warning: Quitting smoking reduces the risk of cancer"?
The answer depends on how confident you are in your ability to quit, according to a study led by researchers at Georgetown Lombardi Comprehensive Cancer Center and published in the journal Nicotine & Tobacco Research.
The research, which involved 740 participants and three D.C. area institutions, ...
To curb violent tendencies, start young
2014-09-15
DURHAM, N.C. -- Aggressive children are less likely to become violent criminals or psychiatrically troubled adults if they receive early intervention, says a new study based on more than two decades of research.
These findings from researchers at Duke, Pennsylvania State and Vanderbilt universities and the University of Washington are based on the Fast Track Project, a multi-faceted program that is one of the largest violence-prevention trials ever funded by the federal government.
Beginning in 1991, the researchers screened nearly 10,000 5-year-old children in Durham, ...
Schizophrenia not a single disease but multiple genetically distinct disorders
2014-09-15
AUDIO:
New research shows that schizophrenia isn't a single disease but a group of eight genetically distinct disorders, each with its own set of symptoms. The finding could be a first...
Click here for more information.
New research shows that schizophrenia isn't a single disease but a group of eight genetically distinct disorders, each with its own set of symptoms. The finding could be a first step toward improved diagnosis and treatment for the debilitating psychiatric illness.
The ...
Vitamin E intake critical during 'the first 1,000 days'
2014-09-15
CORVALLIS, Ore. – Amid conflicting reports about the need for vitamin E and how much is enough, a new analysis published today suggests that adequate levels of this essential micronutrient are especially critical for the very young, the elderly, and women who are or may become pregnant.
A lifelong proper intake of vitamin E is also important, researchers said, but often complicated by the fact that this nutrient is one of the most difficult to obtain through diet alone. It has been estimated that only a tiny fraction of Americans consume enough dietary vitamin E to meet ...
AGA releases new tool to help GIs evaluate and treat Crohn's disease
2014-09-15
Bethesda, MD (Sept. 15, 2014) — The treatment of Crohn's disease is evolving. To help gastroenterologists better identify and manage their Crohn's disease patients, the American Gastroenterological Association (AGA) has created a clinical decision tool to guide GIs in their decision-making process. The "Identification, Assessment, and Initial Medical Treatment in Crohn's Disease Clinical Decision Support Tool," published in Gastroenterology, the official journal of the AGA, synthesizes gastroenterologist's understanding of the disease with data from recent studies to create ...
High-dose opioid prescribing continues to climb
2014-09-12
TORONTO, Sept. 12, 2014 – High-dose opioid prescribing increased by 23 per cent in Canada between 2006 and 2011, despite clinical guidelines recommending that most patients should avoid high-doses of these drugs, according to new research.
Researchers at St. Michael's Hospital and the Institute for Clinical Evaluative Sciences (ICES) found that rates of high-dose opioid dispensing across Canada increased from 781 units per 1,000 people in 2006 to 961 units per 1,000 people in 2011.
"We found that high-dose prescribing was widespread across the country, but the prevalence ...